The main reason for this amendment is to change an inclusion criterion that will enable all eligible subjects to enter this trial directly after completing the treatment period(s) in their parent trial.

The main reason for this amendment is to change an inclusion criterion to also allow eligible subjects from trial LP0162-1346 to enter the extension trial.

The main reason for this amendment is to change exclusion criterion to reflect that a wash-out period is not considered necessary because subjects are allowed to resume investigational medicinal product following 5 half-lives after the last administration of systemic immunosuppressive or immunomodulating drugs and/or systemic corticosteroids. Clarifications on how to handle duplicate assessments (i.e. assessments performed on the same day) between parent trial and trial LP0162-1337 have been added.

The main reason for this amendment is to introduce the option to take skin biopsy samples at selected sites in the subgroup of subjects who had skin biopsy samples in the parent trial LP0162-1325 and to consolidate the 2 screening visits to 1 visit.

The main reason for the amendment is to introduce the possibility for eligible subjects in selected countries of trial LP0162-1334 with adolescent subjects to continue in this long-term extension trial (LP0162-1337, ECZTEND). The purpose is to obtain long-term safety data for adolescent subjects with atopic dermatitis (AD) treated with tralokinumab.

The main reason for this amendment is to extend the collection of long-term safety data for tralokinumab up to 5 years, and at the same time provide subjects the possibility to continue treatment until treatment with tralokinumab is also available to patients outside the clinical trial setting. Subjects from the parent trial LP0162-1334 will have the opportunity to continue for an additional 1-year extension, providing an additional year of safety data for adolescents/young adults. To reduce the burden of frequent site visits for subjects, the amendment will introduce a visit schedule more similar to standard practice for home use. The modified design reduces the number of site visits and instead introduces a mandatory telephone visit in between site visits to ensure close safety monitoring of the subjects. This amendment also introduces the possibility for eligible subjects from 2 new parent trials, LP0162-1343 and TRA-WEI-0015-I, to participate in this long-term extension trial.

The main reason for amendment 9 is to shorten the safety follow-up period from 16 weeks to 4 weeks for subjects transferred from the adolescent parent trial LP0162-1334. Furthermore, changes that were made for the local protocol versions for Japan and Germany have been implemented in the protocol, and the definition of treatment completers has been updated.